Latest News

If you are wondering whether Heidrick & Struggles International is still a smart buy after such a strong run, you are not alone. This is exactly what we are going to unpack here. The stock has climbed 33.9% year to date and is up 30.4% over the last year, while longer term holders have seen gains of 108.8% over 3 years and 122.8% over 5 years, all from a recent close of $59.01. Those gains have come as investors have warmed to the company’s positioning in higher value advisory and leadership...

As the U.S. market navigates a complex landscape with the Dow Jones Industrial Average reaching new heights and tech-heavy indices like the Nasdaq and S&P 500 experiencing pullbacks, investors are closely watching for opportunities amid fluctuating interest rates and economic data. In this environment, identifying stocks that may be undervalued requires careful consideration of their intrinsic worth relative to current market conditions, offering potential value in a diverse portfolio.

The U.S. stock market has been experiencing mixed movements, with the Dow Jones Industrial Average recently setting a new all-time high while the Nasdaq and S&P 500 have pulled back due to concerns over tech stocks. Despite these fluctuations, certain investment opportunities continue to capture attention, particularly in areas that offer affordability and potential growth. Penny stocks, though an outdated term, still represent smaller or newer companies that can provide significant value...

ALK-Abelló has announced that Edward Jordan, a biopharmaceutical executive with more than 30 years of experience, will become Executive Vice President and head of Commercial Operations in North America from January 2026, following the earlier elevation of the region into the Executive Leadership Team to support the Allergy+ strategy. By bringing in a leader with deep allergy and immunology expertise and a history of building US therapeutic markets, ALK-Abelló is clearly prioritizing stronger...

Wondering if Hapag-Lloyd at around €122.90 is a bargain or a value trap right now? This article will walk you through what the current price is really telling us. The stock has bounced 6.6% over the last week and 4.8% over the past month, but is still down 24.3% year to date and 15.7% over the last year, which hints at shifting sentiment and possibly changing risk perceptions. Recent headlines have focused on container shipping demand normalising after the post pandemic surge. At the same...

On November 25, 2025, Loar Holdings Inc. amended its Credit Agreement, increasing its delayed draw term loan commitment by US$175.0 million to US$275.0 million and extending the availability period through September 30, 2026, leaving the full US$275.0 million still undrawn as of that date. This expanded and extended loan capacity, together with fresh analyst coverage positioning Loar as a high-quality aerospace aftermarket M&A compounder, enhances the company’s financial flexibility to...

Del Monte Pacific (SGX:D03) has just posted its Q2 2026 scorecard, with revenue of about $234.9 million, basic EPS of $0.0087 and net income of roughly $16.8 million setting the tone for its latest quarter. The company has seen revenue move from roughly $694.0 million in Q2 2025 to $234.9 million in Q2 2026, while net income swung from a loss of about $22.2 million to a profit of $16.8 million and EPS shifted from a loss of $0.0114 to a profit of $0.0087. This points to a very different...

BillionToOne (BLLN) has just put another big quarter on the board, with Q3 2025 revenue at about $62.8 million and Basic EPS of roughly -$0.20, as investors gauge how fast the top line can outrun still negative earnings. The company has seen revenue move from roughly $34.5 million in early 2024 to about $41.7 million later that year and then to $62.8 million in 2025, while Basic EPS shifted from about -$0.76 to -$1.30 and then to -$0.20 over the same stretch, setting up a story where rapid...

Wondering if Ingevity at around $58.83 is still a smart buy or if the easy money has already been made? You are not alone; this stock has quietly been drawing fresh attention from value focused investors. After a tough few years, the share price has surged, up 12.6% over the last week, 18.8% over the past month, and 48.8% year to date, even though the 3 and 5 year returns are still down 15.5% and 19.7% respectively. Part of this turnaround story reflects shifting sentiment around specialty...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Compañía Cervecerías Unidas (SNSE:CCU) has had a rough week with its share price down 3.7%. We decided to study the...

If you are wondering whether Tapestry is still a buy after its big run, you are not alone. This stock has become a litmus test for how investors value premium brands in a changing consumer landscape. The share price has been on a tear, up 5.2% over the last week, 11.0% over the last month, and 79.4% year to date, capping off a 92.0% 1-year gain and multi-year returns north of 200%. Much of that momentum has been tied to headlines around Tapestry's portfolio strategy and brand investments,...

The UK market has faced challenges recently, with the FTSE 100 index closing lower due to weak trade data from China, highlighting ongoing global economic uncertainties. Despite these broader market fluctuations, penny stocks remain an intriguing investment option for those seeking growth opportunities at lower price points. Although the term "penny stock" might seem outdated, these smaller or newer companies can still offer significant potential when backed by strong financials and solid...

Most readers would already be aware that Toromont Industries' (TSE:TIH) stock increased significantly by 12% over the...

Wondering if Skanska is still good value after its run over the last few years, or if most of the upside is already priced in? This breakdown will help you decide whether to keep watching or start acting. The stock has climbed about 2.0% over the last week, 3.3% year to date and 9.3% over the past year, while its 3 year gain of 60.9% and 5 year gain of 44.6% show that investors have already been rewarded for backing the story. Recent headlines have focused on Skanska winning new...

Temenos AG recently authorized a new share repurchase program of up to CHF 100 million, running until December 30, 2026, with repurchased shares earmarked for general corporate uses such as employee equity plans and potential acquisitions. On the governance side, the Board’s decision to appoint former CFO and interim chief Takis Spiliopoulos as permanent CEO reinforces leadership continuity at a time of capital allocation moves. Next, we’ll examine how the CHF 100 million buyback...

We wouldn't blame KKR Real Estate Finance Trust Inc. ( NYSE:KREF ) shareholders if they were a little worried about the...

Ryman Healthcare (NZSE:RYM) just released half-year numbers that will make investors sit up. Revenue is climbing, but the company has shifted from a solid profit to a net loss. See our latest analysis for Ryman Healthcare. The NZ$2.88 share price reflects a mixed story, with a solid 90 day share price return of 15.66% but a steep year to date share price decline and weak multi year total shareholder returns. This hints that sentiment is only cautiously improving after the earnings setback. If...

Wondering if Ouster's huge run means you are late to the party or staring at an overlooked opportunity? Let's break down what the market is really pricing in here. The stock is up 108.3% year to date and 181.4% over the last year, even after a recent 1.0% dip over 7 days and a modest 3.7% gain across 30 days. This hints that sentiment has shifted fast, and risk perceptions are clearly changing. Much of this excitement has been driven by Ouster's push to scale its lidar technology into...

It looks like Merck & Co., Inc. ( NYSE:MRK ) is about to go ex-dividend in the next three days. The ex-dividend date...

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Passive investing in index funds can generate returns that roughly match the overall market. But the truth is, you can...

Eiffage SA's ( EPA:FGR ) price-to-earnings (or "P/E") ratio of 11.9x might make it look like a buy right now compared...

We wouldn't blame Guardant Health, Inc. ( NASDAQ:GH ) shareholders if they were a little worried about the fact that...